Morgan Stanley set a €70.00 ($81.40) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note released on Thursday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
A number of other research analysts also recently weighed in on FME. Jefferies Financial Group reiterated a buy rating and set a GBX 99 ($1.29) price target on shares of in a report on Friday, June 28th. Goldman Sachs Group set a $13.00 price objective on Ford Motor and gave the company a buy rating in a research report on Thursday, June 13th. Credit Suisse Group set a €50.00 ($58.14) price objective on Fresenius SE & Co KGaA and gave the company a neutral rating in a research report on Monday, May 6th. Nord/LB set a €92.00 ($106.98) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Friday, May 3rd. Finally, JPMorgan Chase & Co. set a €56.70 ($65.93) price objective on Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Monday, June 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average target price of €82.57 ($96.01).
Shares of FME stock opened at €69.70 ($81.05) on Thursday. Fresenius Medical Care AG & Co. KGaA has a 1-year low of €55.44 ($64.47) and a 1-year high of €91.74 ($106.67). The company has a quick ratio of 0.67, a current ratio of 1.02 and a debt-to-equity ratio of 100.05. The stock has a market capitalization of $21.28 billion and a P/E ratio of 10.85. The company’s fifty day simple moving average is €68.10.
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Story: Debt-To-Equity Ratio
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.